First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study

The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shousheng, Jiang, Chang, Yang, Lin, Huang, Jinsheng, Peng, Roujun, Wang, Xiaopai, He, Wenzhuo, Bai, Long, Zhou, Yixin, Zhang, Bei, Xia, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378223/
https://www.ncbi.nlm.nih.gov/pubmed/32704062
http://dx.doi.org/10.1038/s41598-020-69230-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378223/
https://www.ncbi.nlm.nih.gov/pubmed/32704062
http://dx.doi.org/10.1038/s41598-020-69230-5

Ejemplares similares